TC Biopharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, is focused on beginning Proof of Concept preclinical studies to evaluate its lead therapeutic TCB 008 for treatment in monkey pox. According to the announcement, TCBP will partner with a leading infectious disease center or university associated with a similar organization to advance the studies as quickly as possible.
“There are a number of academic papers highlighting a successful immune response to viral infection being heavily reliant on the presence of gamma delta t-cells,” said TC BioPharm CEO Bryan Kobel in the press release. “We continue to look at avenues to expand the therapeutic applications for TCB008, and moving into rapid response for aggressive viral infections is an arena we believe our therapeutic can be immediately impactful. The ability to deliver a frozen/thawed product to these patients to prevent not just the death or extended viral infection in these patients, but also potentially slow the spread of the infectious disease and contain the issue from becoming a global pandemic, would represent a massive global opportunity and market size. We look forward to updating investors as we further this program.”
To view the full press release, visit https://ibn.fm/judx7
About TC Biopharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm is the leader in developing gamma-delta T cell therapies and is the first company to conduct phase 2/pivotal clinical studies in oncology. The company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line, including a phase 2b/3 pivotal trial in treatment of acute myeloid leukemia using the company’s proprietary allogenic CryoTC technology to provide frozen product to clinics worldwide. For more information, please visit www.TCBioPharm.com.
NOTE TO INVESTORS: The latest news and updates relating to TCBP are available in the company’s newsroom at https://ibn.fm/TCBP
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com
BioMedWire is powered by IBN
